Emerging personalized approaches for the management of advanced urothelial carcinoma.

about

Targeting glycogen metabolism in bladder cancer Biomarkers for bladder cancer management: present and future.

P2860

Q27025144-E851EBED-45D0-4C81-B79D-666494AE7DD2 Q34448168-5B80B25F-38AB-41E0-A6F1-E875276E5CDF

P2860

Emerging personalized approaches for the management of advanced urothelial carcinoma.

Item

http://www.wikidata.org/entity/Q38068583

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Emerging personalized approaches for the management of advanced urothelial carcinoma.

@en

type

Item

label

Emerging personalized approaches for the management of advanced urothelial carcinoma.

@en

prefLabel

Emerging personalized approaches for the management of advanced urothelial carcinoma.

@en

P1476

Emerging personalized approaches for the management of advanced urothelial carcinoma.

@en

P2093

Benjamin A Gartrell

http://www.w3.org/2001/XMLSchema#string

Che-Kai Tsao

http://www.w3.org/2001/XMLSchema#string

Matthew D Galsky

http://www.w3.org/2001/XMLSchema#string

P2860

Genome sequencing identifies a basis for everolimus sensitivity

Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study

Expression patterns of erbB receptor family in normal urothelium and transitional cell carcinoma. An immunohistochemical study

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

Screening for epidermal growth factor receptor mutations in lung cancer

Expression patterns of erbB receptor family in normal urothelium and transitional cell carcinoma

Concordant gene expression signatures predict clinical outcomes of cancer patients undergoing systemic therapy

Predicting response to methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy for bladder cancers through genome-wide gene expression profiling.

Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987.

Generation of a concise gene panel for outcome prediction in urinary bladder cancer.

P304

1537-1543

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/ERA.12.141

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

William K. Oh

P577

2012-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23253220

http://www.w3.org/2001/XMLSchema#string

P932

4744482

http://www.w3.org/2001/XMLSchema#string

Emerging personalized approaches for the management of advanced urothelial carcinoma.

about

P2860

P2860

Emerging personalized approaches for the management of advanced urothelial carcinoma.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932